Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. (ORKA) is a US-listed equity tracked across major market indices. Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

The company reports trailing twelve-month revenue of $0 and net loss of $31.82M. Key metrics include a return on equity of -6.5%, a debt-to-equity ratio of 0.04.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for ORKA to support both active traders and long-term investors.